Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.
Zacks·2d ago
Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide
CEO Dave Ricks told CNBC that the first study the company plans to read out for Retatrutide will be on knee pain.
Stocktwits·2d ago
Eli Lilly CEO: Seeing global demand for weight loss drug Mounjaro
Eli Lilly chairman and CEO David Ricks joins CNBC's Squawk on the Street team to discuss its quarterly earnings report that beat estimates, weight loss drug demand, its drug pipeline and more...
CNBC Television-YouTube·2d ago
Pre-markets Down on Questions: Fed, Jobs & Q3 Earnings
Weekly Jobless Claims are not out again this Thursday morning, for the fifth straight week.
Zacks·2d ago
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.